Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 106Pancreatic Neoplasms 31Esophageal Neoplasms 17Esophageal Squamous Cell Carcinoma 11Biliary Tract Neoplasms 11Colorectal Neoplasms 10Cholangiocarcinoma 6Neoplasm Metastasis 5Nasopharyngeal Carcinoma 5Adenocarcinoma 5Recurrence 4Head and Neck Neoplasms 4Gastrointestinal Neoplasms 4Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3Advanced Pancreatic Cancer 3Advanced Gastric Cancer 3Stage IV Gastric Cancer With Metastasis 2Neoplasms 2NSCLC 2Locally Advanced Gastric Cancer 2Gastric Cancer Peritoneal Metastases 2Gastric Adenocarcinoma 2Gallbladder Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2mCRC 1Surgically-Created Resection Cavity 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Oxaliplatin 2Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Borderline Resectable Pancreatic Cancer × S 1 (combination) × Clear all
NCT03850769 2020-03-10

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Peking Union Medical College Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡